Seeking Alpha

William Haynes

 
View William Haynes' StockTalks BY TICKER:
  • William Haynes
    FDA panel vote on proven unsafe drug Meridia (ABT) was split 8:8. This panel may be more sympathetic to lorcaserin (ARNA) than anticipated.
    9/15/10
    Reply
      • William Haynes
        Because obesity is probably the biggest contributor to cancer, ARNA could argue that weight loss from lorcaserin will reduce cancer.
        9/14/10
        Reply
          • William Haynes
            FDA lorcaserin (ARNA) review seems tough, but addressable. Animal cancer is the wild card. But Victoza got approved despite animal cancer.
            9/14/10
            Reply
              • William Haynes
                Meridia certain to be withdrawn (http://bit.ly/bEbyyR). Contrave has an identical BP profile and will likely be rejected by the FDA too.
                9/2/10
                Reply
                  • William Haynes
                    ARNA continues to be undervalued. OREX continues to be overvalued.
                    8/27/10
                    Reply
                      • William Haynes
                        Qnexa (VVUS) failure was predictable months ago based on teratogenicity, cardiac arrhythmias, metabolic acidosis and anxiety/insomnia
                        7/15/10
                        Reply